Skip to content

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Exocrine Pancreatic Dysfunction in Type 1 Diabetes

CFTR and Exocrine Pancreatic Dysfunction in Type 1 Diabetes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05385211
Enrollment
100
Registered
2022-05-23
Start date
2022-04-30
Completion date
2023-08-30
Last updated
2023-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exocrine Pancreatic Insufficiency, Type 1 Diabetes

Keywords

Cystic fibrosis transmembrane regulator, Type 1 diabetes, Hypoglycemia, Exocrine pancreas

Brief summary

This study proposes to examine the contribution of CFTR variants to exocrine pancreatic insufficiency and hypoglycemic risk. Hypoglycemia is one the most frequent complications of type 1 diabetes management. Despite recent innovations, hypoglycemic risk remains high for people living with type 1 diabetes (PWT1D). Recent studies have shown that pancreatic insufficiency could affect hypoglycemic risk. Up to now, there are limited data on the association between pancreatic insufficiency and glucose control (i.e. the frequency and severity of hypoglycemic episodes as well as HbA1c levels). The main objective of this study is to determine the impact of pancreatic insufficiency on glucose control in PWT1D, and to address the role of CFTR variants as potential contributors to pancreatic insufficiency.

Detailed description

In this a one year cross sectional study, we plan to enroll 100 adults living with type 1 diabetes. Patient data will then be separated into two groups based the presence or absence of exocrine pancreatic insufficiency (EPI). EPI will be defined based on the levels of pancreatic enzymes (Amylase; lipase; and trypsinogen). As the prevalence of EPI in people living with type 1 diabetes (PWT1D) is \ 50%, we expect roughly the same number of individuals into both groups (with or without EPI). Variables : Subject data (age, gender, duration of diabetes, age at diagnostic, etc.) will be collected. Glucose variation will be assessed with a continuous glucose monitoring system for 1 month. Briefly we will collect the number and severity of hyperglycemic events, average glucose levels, glycemic variability, etc.. From collected peripheral blood mononuclear cells (PBMCs) we will quantify CFTR function and level of expression, as well as identify CFTR variants by next generation sequencing.

Interventions

OTHERFrequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency

Blood samplings; Glucose monitoring; CFTR variants

Sponsors

Juvenile Diabetes Research Foundation
CollaboratorOTHER
Institut de Recherches Cliniques de Montreal
CollaboratorOTHER
Ciusss de L'Est de l'Île de Montréal
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Type 1 diabetes * Living in Montreal

Exclusion criteria

* Pregnancy, * Use of corticosteroid * Use of medication known to have a relevant impact on glycemic control.

Design outcomes

Primary

MeasureTime frameDescription
Frequency and severity of hypoglycemic events1 monthContinuous glucose monitoring will be used to assess glucose regulation
Exocrine pancreatic insufficiencyBaselineBlood levels of pancreatic enzymes will be measured

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026